ImmunityBio, Inc.

IBRX Nasdaq CIK: 0001326110

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 3530 JOHN HOPKINS COURT, SAN DIEGO, CA, 92121
Mailing Address 3530 JOHN HOPKINS COURT, SAN DIEGO, CA, 92121
Phone (844) 696-5235
Fiscal Year End 1231
EIN 431979754

Financial Overview

FY2025

$501.90M
Total Assets
$265.45M
Cash & Equivalents

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report April 2, 2026 View on SEC
8-K Current report of material events March 31, 2026 View on SEC
4 Insider stock transaction report February 26, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment February 25, 2026 View on SEC
4 Insider stock transaction report February 24, 2026 View on SEC
4 Insider stock transaction report February 24, 2026 View on SEC
4 Insider stock transaction report February 24, 2026 View on SEC
4 Insider stock transaction report February 24, 2026 View on SEC
4 Insider stock transaction report February 24, 2026 View on SEC
4 Insider stock transaction report February 24, 2026 View on SEC

Annual Reports

10-K February 23, 2026
  • Significant revenue growth in 2025, primarily driven by the initial commercialization of ANKTIVA® (N-803).
  • Successful market entry and initial adoption of ANKTIVA® for BCG-unresponsive NMIBC carcinoma in situ (CIS).
View Analysis

Insider Trading

STRONG SELL 2 insiders 8 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.